biologic

Cosentyx

secukinumab

Loss of exclusivityJanuary 2027projected — 12-year biologic exclusivity estimate
CompanyNovartis Pharmaceuticals Corporation

Drug detail

Brand nameCosentyx
Active ingredientsecukinumab
Strength150MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJanuary 2015
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Cosentyx patent cliff — loss of exclusivity January 2027 | CliffBio